Weeks 1 and 2: your first injections and the nausea window
The first two weeks on a GLP-1 medication are primarily about learning the injection routine and tolerating the starting dose. Scale results in this phase are typically modest, and that is expected. Both Wegovy (semaglutide injection, FDA-approved for chronic weight management) and Zepbound (tirzepatide injection, FDA-approved for chronic weight management) begin at doses set deliberately low to help the digestive system adapt.
Nausea is the most commonly reported early side effect. A pooled analysis of the STEP 1, 2, and 3 clinical trials of semaglutide 2.4 mg (Wegovy) found that 43.9% of participants reported nausea at some point during treatment, compared with 16.1% on placebo. These figures are from trials of Wegovy, an FDA-approved drug. Compounded semaglutide is not FDA-approved and has not been evaluated in equivalent clinical trials. Most people report that nausea is worst on injection day and gradually eases over the following four to five days.
Practical steps that tend to reduce nausea in the first two weeks:
- Eat smaller portions and stop at the first sensation of fullness
- Eat slowly, and do not lie flat immediately after meals
- Avoid high-fat and heavily fried foods, which further slow gastric emptying and can worsen symptoms, as noted in a 2026 Frontiers in Endocrinology clinical review of nausea management in GLP-1 therapy
- Stay well-hydrated throughout the day using small, frequent sips rather than large amounts at once
Fatigue, mild stomach discomfort, and changes in bowel habits (both constipation and occasional loose stools) are also common. Contact a clinician if vomiting is severe, persistent, or interferes with keeping fluids down.
Why GLP-1 treatment begins at a low dose
The gradual dose escalation built into every FDA-approved GLP-1 label exists to reduce gastrointestinal side effects, not to delay results. The Wegovy (semaglutide) prescribing information specifies four phases before reaching the maintenance dose: 0.25 mg weekly for weeks 1 through 4, 0.5 mg for weeks 5 through 8, 1.0 mg for weeks 9 through 12, 1.7 mg for weeks 13 through 16, and 2.4 mg as the maintenance dose from week 17 onward. The full therapeutic dose is not reached until roughly four months into treatment.
The Zepbound (tirzepatide) prescribing information follows a comparable structure, starting at 2.5 mg once weekly for the first four weeks and increasing in 2.5 mg steps no sooner than every four weeks, with a maximum dose of 15 mg. The earliest anyone can reach the 15 mg ceiling on the approved schedule is approximately week 21.
These schedules are from the FDA-approved prescribing information for those named drugs. Compounded semaglutide and compounded tirzepatide are not FDA-approved. They are prescribed by individual licensed providers and compounded at licensed pharmacies under separate protocols set by the prescribing clinician.
GLP-1 receptor agonists begin signaling the brain's satiety centers and slowing gastric emptying even at low starting doses, which is why mild appetite reduction can appear before a therapeutic dose is reached. If a provider recommends staying at a lower dose for an additional four weeks because of tolerability, this is a standard clinical decision and does not indicate a problem with the treatment.
Weeks 3 and 4: still on the starter dose
Weeks 3 and 4 are still within the initiation phase, and most people are still on the lowest dose. Per the Wegovy prescribing information, 0.25 mg is labeled as a dose intended to improve tolerability, not as a chronic treatment dose. Some people notice no change in appetite at all during weeks 1 through 4, which is typical and does not indicate the medication will not work.
For many people, nausea begins to ease slightly in weeks 3 and 4 as the body builds tolerance to its current dose level. Energy levels often stabilize compared to the first week. Weight changes at this stage, if any, are modest.
Two practical habits worth starting now, before appetite suppression deepens:
- Tracking food intake. Not to restrict calories arbitrarily, but to understand current eating patterns before hunger cues change significantly. When fullness signals become stronger, it is easy to skip meals and undereat protein without realizing it.
- Setting a loose meal schedule. GLP-1 medications can reduce hunger cues dramatically over time. People who rely entirely on hunger to prompt meals can accidentally undereat. A rough schedule of when to eat reduces that risk, even on days with minimal appetite.
Any medical concerns, questions about dose adjustments, or significant side effects during this period should go directly to the prescribing clinician.
Month 2: when appetite begins to shift
Month 2 is where many people notice the medication's appetite effects becoming more pronounced. For those following the Wegovy titration schedule, the dose steps up from 0.25 mg to 0.5 mg at week 5, and then to 1.0 mg at week 9. Each increase can bring a brief recurrence of nausea, usually milder than the original episode, followed by another adaptation period.
The appetite change during this phase tends to show up in specific, concrete ways: a smaller portion feels satisfying; the urge to snack decreases; interest in high-calorie foods drops in a way that feels almost automatic rather than driven by willpower. A retrospective survey published in Advances in Therapy, the INFORM survey of 550 adults taking injectable semaglutide for weight management, found that before starting treatment, 62% of participants reported constant food-related thoughts throughout the day. While on the medication, that figure fell to 16%, a decline of 46 percentage points.
Weight loss in month 2 is real but moderate. Participants in the STEP 1 trial of Wegovy (semaglutide 2.4 mg, published in the New England Journal of Medicine in 2021) lost approximately 2% of body weight per month on average across the first six months. These results are for Wegovy; compounded semaglutide is not FDA-approved and has not been evaluated in equivalent clinical trials. Individual results depend on starting weight, dose, adherence, and lifestyle.
What research says about food noise quieting
The term "food noise" describes persistent, intrusive thoughts about food, eating, and hunger that occupy mental space throughout the day. This concept has moved from patient forums and social media into formal clinical research. A paper published in Nutrition and Diabetes reviewed the scientific literature and proposed standardized definitions and measurement tools for food noise as a distinct clinical phenomenon, separate from general appetite or calorie intake.
GLP-1 receptor agonists appear to reduce food noise through two overlapping pathways: peripheral signals from the gut that slow gastric emptying and increase satiety hormones, and direct effects on dopamine pathways in the brain's reward circuitry, where food cravings are processed. These combined effects may explain why many people describe food becoming less compelling overall, rather than requiring constant active restraint.
The reduction typically builds gradually. In the first two to four weeks, many people notice little change in food preoccupation. By weeks five to eight, quieting often becomes more apparent. By month three, a meaningful share of patients report the shift feels stable rather than fluctuating week to week. This does not happen at the same pace for everyone. Expecting food noise to vanish after the first injection is unlikely to match the actual experience for most people. The INFORM survey referenced above used FDA-approved injectable semaglutide; the study did not separately evaluate compounded semaglutide. Compounded semaglutide is not FDA-approved and has not been evaluated in equivalent studies.
Consult a clinician if appetite suppression is so strong that eating adequate food becomes difficult, or if cravings return sharply after a period of quieting, as both can signal dose or tolerability issues worth reviewing.
Protein targets and resistance training: building habits in month 2
Lean tissue, not only fat, decreases during weight loss with GLP-1 medications. A 2026 review published in conjunction with a joint advisory from the Obesity Medicine Association, the American Society for Nutrition, the American College of Lifestyle Medicine, and the Obesity Society found that lean tissue loss comprises approximately 26 to 40% of total weight lost during GLP-1 and GLP-1/GIP receptor agonist treatment. In the STEP 1 trial of Wegovy, lean mass decreased by approximately 9.7% alongside a fat mass decrease of approximately 19.3%. These figures are from Wegovy trials; compounded semaglutide has not been evaluated in equivalent body composition studies.
The same 2026 joint advisory recommended protein intake of 1.2 to 1.6 grams per kilogram of body weight per day during GLP-1 therapy to help offset lean mass loss. This is substantially above the standard recommended daily allowance of 0.8 g/kg/day and reflects how difficult it can be to hit protein targets when total calorie intake drops significantly on the medication.
Resistance training 3 to 5 days per week is the lifestyle intervention most consistently identified in the literature to preserve lean mass during GLP-1-driven weight loss, with active clinical trials currently underway to define optimal protocols. Month 2 is a practical time to start: appetite suppression has become real, but the significant fatigue common in weeks 1 through 4 has often eased. Starting with two or three sessions per week and building from there is a reasonable approach. Starting a new exercise routine should be discussed with a clinician first, particularly if there are existing cardiovascular or musculoskeletal conditions.
Month 3: what visible progress looks like and what it does not guarantee
By the end of month 3, most people notice some visible change, though how much varies considerably. In the STEP 1 trial of Wegovy, participants had not yet reached the maintenance dose by the 12-week mark; the 2.4 mg maintenance dose was still weeks away. Average weight loss across the first three months was approximately 4 to 6% of starting body weight in trial participants. Compounded semaglutide is not FDA-approved and has not been evaluated in comparable clinical trials.
In the SURMOUNT-1 trial published in the New England Journal of Medicine in 2022, which studied Zepbound (tirzepatide, FDA-approved for chronic weight management) over 72 weeks, participants lost an average of 16.0% to 22.5% of body weight depending on dose. These results are for Zepbound in a specific trial population; compounded tirzepatide is not FDA-approved and has not been evaluated in equivalent clinical trials. Cross-trial comparison with semaglutide data is limited because these are different trials with different populations and study designs.
A key finding from clinical data on semaglutide (Wegovy) patient response patterns: approximately 82% of participants in semaglutide trials achieved at least 5% weight loss by week 12, while approximately 18% are classified as late responders at that point. Ninety percent of those late responders still reached the 5% threshold by week 72, on average taking about 25 weeks to get there. These figures are from Wegovy (semaglutide 2.4 mg) clinical data; compounded semaglutide is not FDA-approved and has not been evaluated in equivalent clinical trials. A quieter first three months does not reliably predict overall outcomes when treatment continues.
Side effects in month 3: what typically improves
The STEP 5 trial, which followed participants on Wegovy (semaglutide 2.4 mg) for 104 weeks, reported that gastrointestinal adverse events were "mostly mild to moderate and transient, with effects occurring during dose escalation." Only 3.9% of participants in the semaglutide group discontinued treatment due to GI side effects over the full two-year study period. Compounded semaglutide is not FDA-approved and has not been evaluated in equivalent long-term trials.
For most people tolerating the medication well, month 3 brings noticeably less frequent nausea. Occasional nausea can still be triggered by eating too quickly, consuming high-fat foods, or eating while fatigued, but isolated episodes are manageable and much less disruptive than in weeks 1 through 4. Energy levels typically feel more stable than in the early dose-adjustment phase.
What does not always resolve by month 3: constipation, which remains a persistent side effect in some patients throughout treatment. Ongoing management with dietary fiber, adequate hydration, and in some cases a clinician-recommended mild laxative is appropriate for those who experience it. Any new or worsening symptom, including severe abdominal pain, persistent vomiting, or signs of dehydration, warrants a prompt call to a provider regardless of the treatment phase.
First 90 days at a glance
The table below summarizes what most people can reasonably expect during each phase, based on clinical data from trials of FDA-approved GLP-1 medications. Individual experiences vary. Compounded semaglutide and tirzepatide are not FDA-approved and have not been evaluated in equivalent clinical trials. The dose ranges shown reflect the Wegovy (semaglutide) prescribing information.
| Phase | Wegovy dose range | Typical side effects | Appetite and weight | Key habits to establish |
|---|---|---|---|---|
| Weeks 1-4 (month 1) | 0.25 mg weekly (initiation dose) | Nausea (common on injection day), fatigue, GI discomfort, possible constipation | Mild or no appetite change; weight loss if any is modest; body still adapting | Hydration, small slow meals, food schedule, injection technique |
| Weeks 5-8 (month 2, early) | 0.5 mg weekly | Brief nausea recurrence at dose step-up; typically milder than first episode | Appetite suppression deepening; food noise reducing for many; food cravings often dropping | Protein target (1.2-1.6 g/kg/day), introduce resistance training 2-3 days/week |
| Weeks 9-12 (month 3) | 1.0 mg weekly (still below maintenance) | GI side effects typically easing; constipation may persist; energy stabilizing | Visible weight changes for most; 4-6% average in Wegovy trials at this point | Provider check-in, assess response and tolerance, build resistance training to 3 days/week |
Your first provider check-in: topics worth raising
A follow-up visit with a prescribing clinician is typically scheduled around week 8 to 12, often at or shortly after the first dose step-up, to assess tolerability and early response. This check-in is more important than many patients expect, because it shapes the rest of the dose escalation path.
Topics worth raising at that visit:
- Side effects that are still interfering. If nausea, constipation, or fatigue is ongoing and disruptive, this is the right moment to discuss dose timing, meal composition strategies, or whether dose escalation should be slowed for another four weeks.
- Weight trajectory. Ask the provider what progress looks like for this specific treatment protocol at this point, rather than applying benchmarks from other sources. Response varies by individual, and the prescribing clinician has the most complete picture.
- Protein and exercise habits. A clinician or registered dietitian can evaluate whether protein intake is adequate given appetite changes and current food preferences, and whether exercise is appropriately calibrated to protect lean mass.
- Medications and relevant lab values. Some medications, including those managing blood glucose, may need adjustment as weight changes. Liver enzymes, kidney function, and thyroid status (where relevant) are worth reviewing at a follow-up visit.
- Mental and emotional changes. Some patients notice shifts in mood or their relationship with food during treatment. These are worth discussing openly with a provider.
Clinical guidance suggests that treatment response at 12 weeks on the full maintenance dose is a meaningful checkpoint. Since most people have not reached maintenance by week 12, providers generally evaluate response at the point when the patient has been on a stable full dose for at least four weeks. A slow start at month 3 does not automatically mean the treatment is not working, as the late-responder data above makes clear. This is a conversation to have with the prescribing clinician, not a self-determined cutoff.